Cellestia Biotech

Cellestia Biotech is a biotech company in Basel, Switzerland, founded in 2015. It has raised $45.0M across 2 rounds, most recently a $25.0M Series B in December 2019.

Pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers.

Headquarters
Basel
Employees
11–50
Founded
2015
Business Model
B2B
Total Funding
$45.0M
Last Round
$25.0M Series BDec 2019
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 1 investor for this company. The full record is or through the API.

About

Cellestia Biotech is a clinical-stage biopharmaceutical company developing first-in-class therapeutics targeting the Notch signaling pathway for the treatment of multi-drug resistant cancers and autoimmune diseases. Its lead candidate CB-103, an oral pan-Notch inhibitor, has demonstrated safety and biological activity in Phase 1 trials and is advancing into Phase 2 for hematologic and solid tumor cancers, as well as proof-of-concept studies in graft-versus-host disease. Founded on pioneering academic research, Cellestia addresses cancers where conventional therapies fail by exploiting a novel mode of transcriptional inhibition distinct from prior Notch-targeting approaches.

Summary

It lists 11–50 employees. It has raised $45.0M in total across 2 rounds, most recently a $25.0M Series B round in Dec 2019. Investors include Partners Investment.

Funding History

Data from Indexed.vcUpdated
Series BSeries BDec 2019
$25.0M

Sign up to see all 2 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Cellestia Biotech on Indexed.vc
<a href="https://indexed.vc/companies/cellestia-biotech"><img src="https://indexed.vc/api/badge/company/cellestia-biotech" alt="Cellestia Biotech on Indexed.vc" width="260" height="76" /></a>